FUNDERS UPDATE- BMGF. Third HIV Env Manufacturing Workshop Sponsored by DAIDS-NIAID-NIH and the HIV Global Vaccine Enterprise July 20-21, 2017

Size: px
Start display at page:

Download "FUNDERS UPDATE- BMGF. Third HIV Env Manufacturing Workshop Sponsored by DAIDS-NIAID-NIH and the HIV Global Vaccine Enterprise July 20-21, 2017"

Transcription

1 FUNDERS UPDATE- BMGF Third HIV Env Manufacturing Workshop Sponsored by DAIDS-NIAID-NIH and the HIV Global Vaccine Enterprise July 20-21, 2017 Susan Barnett Senior Program Officer, Product and Clinical Development HIV Program

2 STRATEGIC VISION OF OUR HIV PROGRAM Accelerate the decline of the global burden and incidence of HIV infection by ensuring development and use of impactful prevention and treatment interventions Bill & Melinda Gates Foundation 2

3 HIV PROGRAM INTEGRATED INITIATIVES Strategic areas Increase the fraction of PLHIV initiated on effective highly suppressive treatment, particularly in high transmission populations Increase the fraction of PLHIV who sustain effective highly suppressive treatment Optimize the use of existing prevention interventions to decrease incidence Develop effective long-acting prevention interventions to further decrease incidence Develop a highly efficacious and broadly used vaccine to achieve the greatest impact on decreasing incidence Cross-cutting Initiatives HIV diagnosis and linkage of PLHIV to therapy in high-transmission populations Retention of PLHIV on effective suppressive therapy Use of existing prevention interventions Long-acting anti-retrovirals development Prophylactic neutralizing antibody and biologics development Effective vaccine development Resources and policies Defining and understanding the burden and incidence of HIV infection Bill & Melinda Gates Foundation 3

4 VISION: EFFECTIVE VACCINE DEVELOPMENT Broad coverage of a vaccine with high efficacy and durable protection will transform the HIV epidemic by dramatically reducing incidence. 4

5 ADVANCED DEVELOPMENT PROGRAMS PRECLINICAL/EARLY DEVELOPMENT ALVAC/gp120/MF59 Ad26/gp140 VSVΔG Chimera hcmv-hiv P5 Janssen IAVI Picker/VirBio RV144 Trial: 31% 3.5 yrs, 60% VE at 12 mos Multiple immune correlates of risk defined Added boost, MF59 aim to improve magnitude and duration of response Need to repeat trial in humans to validate the result with P5 clade C products in RSA Go decision in May 2016 for Phase 2b efficacy trial (HVTN 702) - opened Oct 2016 Phase I safety & immunogenicity studies ongoing Need human efficacy trial to validate NHP protection correlated to non-nabs Q GNG decision for Phase 2b efficacy trial (HVTN 705) VSV protein-expressing vector demonstrates significant protection in NHP model Elicits specific non-neutralizing antibody response that appears to correlate with protection Repeating NHP study to confirm result in larger numbers of animals in parallel with structural/physical analysis of vector Preparatory work ongoing for potential first-in-human clinical studies Clinical testing of the prototype HCMV-vector to demonstrate safety and ability of the vector to recapitulate the magnitude and novel immune responses induced in the NHP model Challenges developing manufacturing process to support initial clinical studies $20M PRI to VirBio. Modifying program to incorporate VirBio capabilities 5

6 HIV ENV-RELATED VACCINE INVESTMENTS AND ACTIVITIES Advanced HIV Vaccine Development Manufacture of bivalent subtype C gp120 boost for P5 clinical program (1086.C, TV1.C) Cell lines and methods for future production post-rv144 gp120 boosts (A244.AE, 6420.B) Phase 2b/3 clinical studies with lead candidates (P5, Janssen) to evaluate whether the efficacy and putative correlates of risk observed in prior studies can be replicated in a southern Africa population. Exploratory Research and Early Development Design and develop Env immunogens that induce broadly active neutralizing antibodies in animal models and evaluate in early phase clinical studies. Provide high quality, standardized immune assays, statistical services, data platforms and product development support services in order to substantially improve the translational efficiency and quality of promising candidate vaccines. Bill & Melinda Gates Foundation 6

7 CAVD COLLABORATIVE MODEL (2005-PRESENT) Vaccine Discovery Consortia (VDC) brought together: To form communities of interest centered around scientific ideas To share prepublication data To exchange knowledge and ideas Central Service Facilities (CSF) provide: Best-in-class services to VDCs Enable comparative analysis of standardized data Enable translational efficiency Alliance Management facilitates via: Scientific & logistical coordination and collaboration Incentives for sharing: legal agreements, contingent funding Mechanisms for sharing: web portal, meetings Bill & Melinda Gates Foundation

8 CAVD AS A TRANSLATIONAL ENGINE CAVD-I (RFP in 2005) Diversified pipeline of novel product concepts Big science approach collaboration, coordination, data-sharing Milestones based, emphasis on project management Centralized assay capacity for standardized comparisons CAVD-II (RFPs in 2010/2011) Focus on critical underfunded areas (replicating vectors, non-neutral. Abs, mucosal, passive immunization) Shorter, smaller grants with tighter management, more hard milestones linked to payments Vaccine Product Development Center (VXPDC at IAVI) created to provide a translational emphasis to the largely academic network CAVD-III (2012 present) Leveraging of CAVD model to 1) support community of functional cure-related grants and 2) create a similar model to accelerate vaccine translation across Global Health Build on prior investments to advance promising concepts to clinical evaluation Bill & Melinda Gates Foundation 8

9 CAVD VACCINE PORTFOLIO-FROM CONCEPT TO CLINIC Concept Preclinical Clinical Active Advanced Clinical Development +/- DNA +/- ALVAC + clade C gp120s + MF59/ASO1b (correlates program) ALVAC + clade C gp120s/mf59 (Phase 2b) (P5) Ad26.Mos.HIV + gp140 (Janssen) CMV NAC & Protective Ab-inducing Novel vectors & Immunogens Efficient Translation Services & Platforms pp71 UL expressing HCMVgag vector (Picker) HLA-E Restricted CD8 Responses (McMichael) Trimer & epitope-based immunogens Next-gen SOSIP trimers (Moore) gp140 proteins (Barouch) Nearest neighbor (Kelsoe) Adjuvanted nanoparticle ENV (Pulendran) MPER-nanoparticle (Reinherz) Glycan-modified Env (Alter) Correlates of protection (Alter) Llama Anti-Env Immunogen (Jolicoeur) Ab effector function (Ackerman/Alter) GH-VAP (Atreca, IDRI, Stanford, Lee), Kymab pp71 UL deletant HCMVgag vector (Picker) BG505 SOSIP Adj Comparison (McElrath) eod-gt8 (Schief) MPER-Peptide Liposome (Haynes) Designer SHIVs (Shaw) FLSCgp120-CD4 (Gallo) DNA gp140 (Shattock) VSV (Parks) DNA + MVA (mosaic vs. cons vs. wt) (Haynes) rcad26 (Barouch) Vx Product Development Center (IAVI) GLP Protein Core (Haynes) Env Analytics (Ward) Ab Vx Imm Monitoring Center (Montefiori/Seaman) Cellular Vx Imm Monitoring Center (Koup) Vx Immunology Statistical Center (Gottardo)

10 VXPDC SERVICES FOR CLINICAL PRODUCT DEVELOPMENT The VxPDC at IAVI (T. Hassell, PI) delivers value by applying the knowledge and experience of trusted professionals across the unique service areas required for vaccine development to accelerate the path from bench to clinic Project Management & Leadership Drive process with efficiency and support development / project planning (e.g., timeline, milestones, budget, deliverables) Pre-Clinical Development Process & Product Development Manufacturing Management Quality Assurance Regulatory Management Clinical Development Advise on design and outcome of toxicology studies, and facilitate data management, sample testing and tissue binding studies Identify specialized CROs / other contractors and manage the relationship throughout the development process Accelerate manufacturing by ensuring all systems and processes comply with required standards, and support assay development Support quality management by conducting audit of vendors, providing quality standards, and managing release of investigational products Provide regulatory expertise to support CTA/IND submissions (incl. sponsorship as needed); track health authority correspondences Build clinical strategy and protocol design incl. identifying sites for clinical testing, TPP development, and data management 10

11 DESIGN AND DEVELOP IMMUNOGENS THAT INDUCE BROADLY ACTIVE NEUTRALIZING ANTIBODIES GL-DIRECTED IMMUNOGENs WELL-ORDERED TRIMERs GL: Can we prime Ab responses to initiate bnab lineages with appropriately designed epitope immunogens? Most often followed by a trimer Can we induce bnabs by immunization (either serially or as a cocktail) with variants of wellordered trimers? [SOSIP;NFL;Foldon] eod-gt8 NAC (eod-gt8) Moore (GL trimers) NAC Moore Barouch Prime Ab responses to initiate bnab lineages with appropriately designed epitope immunogens or trimers eod-gt8 60-mer (Schief) to activate CD4bs class bnabs via germline binding Germline trimers (Moore) to activate CD4bs, V2 apex germline

12 DEVELOPMENT OF MPER PEPTIDE LIPOSOME VACCINE TO INITIATE 2F5 B CELL LINEAGE (B. HAYNES) Bill & Melinda Gates Foundation 12

13 RELATED PRESENTATIONS TODAY SHORT UPDATES AND ONGOING PROGRAMS BG505 SOSIP.664 Antu Dey (IAVI) eod-gt68 60mer Vadim Tsvnetvitsky (IAVI) GTH1-656 MPER peptide liposome Vadim Tsvnetvitsky PRODUCT DEVELOPMENT FOR EARLY STAGE CLINICAL VACCINE STUDIES Accelerated Product Development for Ph 1/2 Balancing Science, Time, Cost Antu Dey Bill & Melinda Gates Foundation 13

14 THANK YOU Bill & Melinda Gates Foundation 14

June 11, 2015 Michael Pensiero, VTRB A workshop sponsored by the Division of AIDS and the Global HIV Vaccine Enterprise

June 11, 2015 Michael Pensiero, VTRB A workshop sponsored by the Division of AIDS and the Global HIV Vaccine Enterprise HIV Envelope Manufacturing Workshop June 11, 2015 Michael Pensiero, VTRB A workshop sponsored by the Division of AIDS and the Global HIV Vaccine Enterprise Presentation Outline HIV Env Protein Manufacturing

More information

Letter from the CEO. Dear Friends of IAVI,

Letter from the CEO. Dear Friends of IAVI, IAVI Annual Report 2017 Letter from the CEO Dear Friends of IAVI, We are pleased to present an overview of the progress IAVI and partners have made in 2017 toward our pursuit of the development of vaccines

More information

Planned Vaccine Trials to Follow-up on RV 144. Merlin Robb, MD Deputy Director for Clinical Research MHRP

Planned Vaccine Trials to Follow-up on RV 144. Merlin Robb, MD Deputy Director for Clinical Research MHRP Planned Vaccine Trials to Follow-up on RV 144 Merlin Robb, MD Deputy Director for Clinical Research MHRP Planned studies are mutually reinforcing and will amplify public health impact and regional relevance

More information

HIV Vaccine Clinical Trials at CIDRZ

HIV Vaccine Clinical Trials at CIDRZ HIV Vaccine Clinical Trials at CIDRZ Developing a Safe and Effective Vaccine for Prevention of HIV Infections Globally Christine Namakobo Senior Research Nurse Matero Clinical Research Site State of Global

More information

SAMRC S RESPONSE TO HIV & TB: WALKING THE TALK: MOVING TO CONTROL

SAMRC S RESPONSE TO HIV & TB: WALKING THE TALK: MOVING TO CONTROL SAMRC S RESPONSE TO HIV & TB: WALKING THE TALK: MOVING TO CONTROL Glenda Gray President & CEO SAMRC 1 SA AIDS 2017 Durban 15 June 2017 Partner logo LEADERSHIP IN A TIME OF UNCERTAINTY 2 BASELINE BUDGET

More information

Diversifying the Pipeline of Product Concepts for an HIV Vaccine. RFP Overview and Guidelines

Diversifying the Pipeline of Product Concepts for an HIV Vaccine. RFP Overview and Guidelines Diversifying the Pipeline of Product Concepts for an HIV Vaccine RFP Overview and Guidelines 1 Table of Contents 1. Introduction. 3 2. Background a. Foundation s HIV Vaccine Strategy 3 b. CAVD Framework..

More information

Case study of formulating two Subtype C gp120 proteins

Case study of formulating two Subtype C gp120 proteins Case study of formulating two Subtype C gp120 proteins Antu Dey, DPhil. Senior Director, IAVI (formerly at GSK Vaccines) Associate Project Leader HIV Research Head Formulation Sciences & Process Development

More information

HVTN P5 Vaccine Trials

HVTN P5 Vaccine Trials HVTN P5 Vaccine Trials Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali, Rwanda 16-17 March 2015 HVTN Mission

More information

The Kitchen Sink. Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona

The Kitchen Sink. Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona The Kitchen Sink Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona The only important slide of my presentation. All efficacy trial in

More information

IVI STRATEGY ARTICULATION. October 12, 2015

IVI STRATEGY ARTICULATION. October 12, 2015 IVI STRATEGY ARTICULATION October 12, 2015 Overall messages for today Our Vision and Mission are as relevant today as they have ever been We need to focus on the diseases and activities where we can have

More information

A Quarterly Update on HIV Prevention Research. Vol. 8 No. 2

A Quarterly Update on HIV Prevention Research. Vol. 8 No. 2 What is it? What could it do? Key Facts Antibodies Passive immunization is the transfer of pre-made antibodies to a person. Passive immunization using today's pre-made antibodies can involve infusion delivered

More information

Novel Vaccine Products for Planned Phase I Immunogenicity Studies in Infants

Novel Vaccine Products for Planned Phase I Immunogenicity Studies in Infants Office of AIDS Research Novel Vaccine Products for Planned Phase I Immunogenicity Studies in Infants L. Jean Patterson, PhD Office of AIDS Research, NIH February 7, 2017 Office of AIDS Research OAR Responsibilities

More information

May HIV Vaccines: The Basics

May HIV Vaccines: The Basics May 2018 HIV Vaccines: The Basics Presentation Overview What is a vaccine? How would an HIV vaccine work? Where are we in the search? What is needed now? What is a Vaccine? A substance that teaches the

More information

Progress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH. Division of Infectious Diseases Columbia University Medical Center

Progress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH. Division of Infectious Diseases Columbia University Medical Center Progress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH Division of Infectious Diseases Columbia University Medical Center 1 Outline A short history of HIV vaccine design and development Describe

More information

Third Env Manufacturing Workshop July 20 21, July 20, 2017 Mary Marovich, M.D. Director, Vaccine Research Program

Third Env Manufacturing Workshop July 20 21, July 20, 2017 Mary Marovich, M.D. Director, Vaccine Research Program Third Env Manufacturing Workshop July 20 21, 2017 July 20, 2017 Mary Marovich, M.D. Director, Vaccine Research Program Presentation Outline Importance and Impact of an HIV Vaccine DAIDS/VRP Programmatic

More information

Current State of HIV Vaccine Development

Current State of HIV Vaccine Development Current State of HIV Vaccine Development Sandhya Vasan, MD US Military HIV Research Program Henry M. Jackson Foundation Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand AVAC HVAD

More information

The Collaboration for AIDS Vaccine Discovery. 10th Annual Meeting. Grantee Profiles. December 7 9, 2015 Seattle, Washington

The Collaboration for AIDS Vaccine Discovery. 10th Annual Meeting. Grantee Profiles. December 7 9, 2015 Seattle, Washington The Collaboration for AIDS Vaccine Discovery 10th Annual Meeting Profiles December 7 9, 2015 Seattle, Washington Table of Contents Ackerman/Alter: Leveraging Antibody Effector Function 4 Alter: A Genetic

More information

Lynn Morris. "Plan B"- bnabs for HIV prevention

Lynn Morris. Plan B- bnabs for HIV prevention "Plan B"- bnabs for HIV prevention Lynn Morris National Institute for Communicable Diseases, a division of the National Health Laboratory Service (NHLS) of South Africa, University of the Witwatersrand,

More information

EMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV. (Summary of the recommendations from an Enterprise Working Group)

EMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV. (Summary of the recommendations from an Enterprise Working Group) AIDS Vaccine 07, Seattle, August 20-23, 2007 EMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV (Summary of the recommendations from an Enterprise Working Group) The Working Group Reston, Virginia,

More information

The Value of Product Development Partnerships in Vaccine Innovation. Hansi J. Dean International AIDS Vaccine Initiative

The Value of Product Development Partnerships in Vaccine Innovation. Hansi J. Dean International AIDS Vaccine Initiative The Value of Product Development Partnerships in Vaccine Innovation Hansi J. Dean International AIDS Vaccine Initiative The Product Development Partnership Model A non-profit partnership of public and

More information

Advancing HIV Vaccines into Efficacy studies. Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland

Advancing HIV Vaccines into Efficacy studies. Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland Advancing HIV Vaccines into Efficacy studies Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland What we need to end AIDS: controlling viremia New classes of Drugs Point of care viral load &

More information

HIV/AIDS: vaccines and alternate strategies for treatment and prevention

HIV/AIDS: vaccines and alternate strategies for treatment and prevention Ann. N.Y. Acad. Sci. ISSN 0077-8923 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Online Meeting Report HIV/AIDS: vaccines and alternate strategies for treatment and prevention Yegor Voronin 1 and Sanjay

More information

Global HIV Vaccine Enterprise Strategic Plan

Global HIV Vaccine Enterprise Strategic Plan Global HIV Vaccine Enterprise Strategic Plan 2018-2023 Foreword For over a decade, the Global HIV Vaccine Enterprise (the Enterprise) has played a unique and essential role as a neutral convener and facilitator,

More information

Comments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of Our forward looking

Comments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of Our forward looking EBOLA HIV January 2015 Comments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of 1995. Our forward looking statements represent our current

More information

4/14/2016. HIV Vaccines and Immunoprotection: Where Are We? Learning Objectives. After attending this presentation, participants will be able to:

4/14/2016. HIV Vaccines and Immunoprotection: Where Are We? Learning Objectives. After attending this presentation, participants will be able to: HIV Vaccines and Immunoprotection: Where Are We? Mark J. Mulligan, MD, FIDSA Distinguished Professor of Medicine Emory University School of Medicine Atlanta, Georgia FINAL: 04/01/16 Atlanta, Georgia: Friday,

More information

Trials & Tribulations: on the way to cure: where do HIV Vaccines fit in? Glenda Gray SA HIV Clinicians Society Conference April, 2016

Trials & Tribulations: on the way to cure: where do HIV Vaccines fit in? Glenda Gray SA HIV Clinicians Society Conference April, 2016 Trials & Tribulations: on the way to cure: where do HIV Vaccines fit in? Glenda Gray SA HIV Clinicians Society Conference 2016 13-16 April, 2016 Scope Rationale for an HIV vaccine RV144 study in Thailand

More information

Correlates of Immunity: RV144 - Lessons Learned

Correlates of Immunity: RV144 - Lessons Learned Correlates of Immunity: RV144 - Lessons Learned US Military HIV Research Program (MHRP) Nelson L. Michael, MD, PhD AIDS Vaccine 2010, Atlanta GA 01 October 2010 Outline RV 144 Correlates Discovery Towards

More information

Evaluation of lead HIV-1 vaccine regimen in APPROACH:

Evaluation of lead HIV-1 vaccine regimen in APPROACH: Evaluation of lead HIV-1 vaccine regimen in : Phase 1/2a study testing heterologous prime boost regimens using mosaic Ad26 and MVA vectors combined with Env protein Hanneke Schuitemaker Martin Freeman,

More information

HIV: RV 144 prime boost HIV vaccine efficacy study

HIV: RV 144 prime boost HIV vaccine efficacy study HIV: RV 144 prime boost HIV vaccine efficacy study Nelson L. Michael, M.D., Ph.D Colonel, Medical Corps, U.S. Army Director US Military HIV Research Program (MHRP) Walter Reed Army Institute of Research

More information

HIV and Challenges of Vaccine Development

HIV and Challenges of Vaccine Development Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV and Challenges of Vaccine Development Richard A. Koup, MD INTEREST

More information

HIV Vaccine. 15 September 2016 นพ.นคร เปรมศร ผ อ านวยการส าน กงาน โครงการศ กษาว คซ นเอดส ทดลอง

HIV Vaccine. 15 September 2016 นพ.นคร เปรมศร ผ อ านวยการส าน กงาน โครงการศ กษาว คซ นเอดส ทดลอง HIV Vaccine 15 September 2016 นพ.นคร เปรมศร ผ อ านวยการส าน กงาน โครงการศ กษาว คซ นเอดส ทดลอง GLOBAL STATISTICS 2015 17 million people were accessing antiretroviral therapy 36.7 million people globally

More information

International AIDS Vaccine Initiative. Strategic Plan

International AIDS Vaccine Initiative. Strategic Plan International AIDS Vaccine Initiative Strategic Plan 2011-2015 MESSAGE FROM THE PRESIDENT There has never been a more exciting time to be involved in AIDS vaccine development. In just the past three years,

More information

HVTN Laboratory Program: Immunogenicity and Research Assays

HVTN Laboratory Program: Immunogenicity and Research Assays HVTN Laboratory Program: Immunogenicity and Research Assays Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali,

More information

The History of HIV Vaccine Development

The History of HIV Vaccine Development The History of HIV Vaccine Development a short story on 30 years of research å Dr. Jill Gilmour International AIDS Vaccine Initiative Barcelona, 6 October 2013 IAVI is a product-development partnership

More information

New Preventive Technology: Providing New Options to Stop the Spread of HIV/AIDS. Dublin, Ireland. June 24, AIDS Vaccines.

New Preventive Technology: Providing New Options to Stop the Spread of HIV/AIDS. Dublin, Ireland. June 24, AIDS Vaccines. New Preventive Technology: Providing New Options to Stop the Spread of HIV/AIDS Dublin, Ireland June 24, 2004 AIDS Vaccines - An R&D Briefing This paper has been prepared by the International AIDS Vaccine

More information

GOVX-B11: A Clade B HIV Vaccine for the Developed World

GOVX-B11: A Clade B HIV Vaccine for the Developed World GeoVax Labs, Inc. 19 Lake Park Drive Suite 3 Atlanta, GA 3 (678) 384-72 GOVX-B11: A Clade B HIV Vaccine for the Developed World Executive summary: GOVX-B11 is a Clade B HIV vaccine targeted for use in

More information

HIV cure: current status and implications for the future

HIV cure: current status and implications for the future HIV cure: current status and implications for the future Carolyn Williamson, PhD Head of Medical Virology, Faculty Health Sciences, University of Cape Town CAPRISA Research Associate, Centre of Excellence

More information

Ongoing HVTN Trials (Enrolling, In Follow-up, and in Long Term Follow-up)

Ongoing HVTN Trials (Enrolling, In Follow-up, and in Long Term Follow-up) Ongoing HVTN Trials (, In, and in ) HVTN 085 90 HVTN VRC rad5 multiclade 02/2012 Boston - Brigham; Chicago; Nashville; New York - NYBC; New York - NYBC - Bronx; Philadelphia; Rochester; San Francisco;

More information

24 26 January 2013, Hong Kong SAR, CHINA. TITLE from VIEW and SLIDE MASTER February 27, 2013

24 26 January 2013, Hong Kong SAR, CHINA. TITLE from VIEW and SLIDE MASTER February 27, 2013 The first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses 24 26 January 2013, Hong Kong SAR, CHINA 1 TITLE

More information

ADVOCACY IN UNCERTAIN TIMES. A call to action HIV VACCINE AWARENESS DAY MAY 18

ADVOCACY IN UNCERTAIN TIMES. A call to action HIV VACCINE AWARENESS DAY MAY 18 ADVOCACY IN UNCERTAIN TIMES A call to action HIV VACCINE AWARENESS DAY 2017 MAY 18 2 HIV VACCINE AWARENESS DAY 2017 POLITICAL WILL A call to action These are hectic times. There is more information coming

More information

Why are validated immunogenicity assays important for HIV vaccine development?

Why are validated immunogenicity assays important for HIV vaccine development? Why are validated immunogenicity assays important for HIV vaccine development? There is a need to compare immunogenicity of products in the pipeline, when similar or different in class when developed by

More information

Encouraging Partnership and Collaboration for Success in the Field of R&D for Global Health

Encouraging Partnership and Collaboration for Success in the Field of R&D for Global Health Encouraging Partnership and Collaboration for Success in the Field of R&D for Global Health Fil Randazzo, Ph.D. Deputy Director Global Health Discovery & Translational Sciences EVERY PERSON DESERVES THE

More information

Should There be Further Efficacy Testing of T-T cell Based Vaccines that do not Induce Broadly Neutralizing Antibodies?

Should There be Further Efficacy Testing of T-T cell Based Vaccines that do not Induce Broadly Neutralizing Antibodies? Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Should There be Further Efficacy

More information

Novel Heterologous Prime-Boost Vaccine Strategies for HIV. Dan Barouch April 18, 2012

Novel Heterologous Prime-Boost Vaccine Strategies for HIV. Dan Barouch April 18, 2012 Novel Heterologous Prime-Boost Vaccine Strategies for HIV Dan Barouch April 18, 2012 Desired Features of a Next Generation HIV-1 Vaccine Candidate The RV1 study suggests that an HIV-1 vaccine is possible

More information

Kymouse, Kymab s human antibody discovery platform, successfully demonstrates steps to developing HIV vaccine

Kymouse, Kymab s human antibody discovery platform, successfully demonstrates steps to developing HIV vaccine Kymouse, Kymab s human antibody discovery platform, successfully demonstrates steps to developing HIV vaccine Kymab, The Scripps Research Institute and International AIDS Vaccine Initiative collaboration

More information

Professor Andrew McMichael

Professor Andrew McMichael BHIVA AUTUMN CONFERENCE 2011 Including CHIVA Parallel Sessions Professor Andrew McMichael University of Oxford 17 18 November 2011, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE

More information

Faculty/Presenter Disclosure. HIV Update Outline. Undetectable = Untransmissable HTPN 052. Partner Opposites attract 9/28/2018

Faculty/Presenter Disclosure. HIV Update Outline. Undetectable = Untransmissable HTPN 052. Partner Opposites attract 9/28/2018 Faculty/Presenter Disclosure HIV Update 2018 Dr. Joss de Wet Clinical Assistant Professor Family Medicine UBC Faculty: Joss de Wet Relationships with financial sponsors: Speakers Bureau/Honoraria: Gilead,

More information

The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise

The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise COMMENTARY The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise The Council of the Global HIV Vaccine Enterprise 1 1 Complete lists of authors and affiliations appear at the end of this

More information

Press conference abstracts Vaccine and Antibody Research Monday, 22 October 2018

Press conference abstracts Vaccine and Antibody Research Monday, 22 October 2018 Press conference abstracts Vaccine and Antibody Research Monday, 22 October 2018 OA02.05LB Vaccine-induced Gene Signature Correlates with Protection against Acquisition in Three Independent Vaccine Efficacy

More information

Trial Collaborators Start Date* Sites Stage HVTN BMGF IPPOX EuroVacc GSID. HVTN DAIDS GSK Sanofi Jun 2017

Trial Collaborators Start Date* Sites Stage HVTN BMGF IPPOX EuroVacc GSID. HVTN DAIDS GSK Sanofi Jun 2017 Ongoing s:, In, Health/AESI Contact(s) 096/EV04 106 107 108 110 A phase 1 double blind placebo-controlled clinical trial to evaluate the safety and to compare the priming ability of NYVAC alone versus

More information

Update on Tuberculosis Vaccines

Update on Tuberculosis Vaccines March 27, 2014 Update on Tuberculosis Vaccines - 2014 Tom Evans MD CEO, Aeras TB is Mother Nature s AERAS GLOBAL number TB VACCINE one FOUNDATION killer over the past centuries TB is spread through the

More information

Supplementary information. Early development of broad neutralizing antibodies in HIV-1 infected infants

Supplementary information. Early development of broad neutralizing antibodies in HIV-1 infected infants Supplementary information Early development of broad neutralizing antibodies in HIV-1 infected infants Leslie Goo, Vrasha Chohan, Ruth Nduati, Julie Overbaugh Supplementary Figure 1. Neutralization profile

More information

A Path to an HIV Vaccine: GSID Consortium Activities. Faruk Sinangil, PhD 4th Annual CAVD Meeting Miami, FL December 1-4, 2009

A Path to an HIV Vaccine: GSID Consortium Activities. Faruk Sinangil, PhD 4th Annual CAVD Meeting Miami, FL December 1-4, 2009 A Path to an HIV Vaccine: GSID Consortium Activities Faruk Sinangil, PhD 4th Annual CAVD Meeting Miami, FL December 1-4, 2009 Project Goals Acquire and disseminate information that will contribute to the

More information

VACCINE MARKETS OVERVIEW SESSION

VACCINE MARKETS OVERVIEW SESSION VACCINE MARKETS OVERVIEW SESSION Robyn Iqbal Program Officer, Vaccine Delivery Market Dynamics UNICEF SD Manufacturers Meeting Copenhagen October 8, 2014 DRAFT Bill & Melinda Gates Foundation DISCUSSION

More information

TB Vaccine Research and Development: Progress, Strategies and Controversies

TB Vaccine Research and Development: Progress, Strategies and Controversies 15 March 2016 GVIRF Global Forum Johannesburg, South Africa TB Vaccine Research and Development: Progress, Strategies and Controversies Lewis Schrager, M.D. V.P., Scientific Affairs Rockville, MD USA Source:

More information

Catalytic Framework to End AIDS, TB and Eliminate Malaria in Africa by 2030

Catalytic Framework to End AIDS, TB and Eliminate Malaria in Africa by 2030 Catalytic Framework to End AIDS, TB and Eliminate Malaria in Africa by 2030 Introduction The Catalytic Framework to End AIDS, TB and Eliminate Malaria in Africa by 2030 provides an overarching policy framework

More information

Vectored Vaccines for HIV: Status and Path Forward. Rick King International AIDS Vaccine Initiative

Vectored Vaccines for HIV: Status and Path Forward. Rick King International AIDS Vaccine Initiative Vectored Vaccines for HIV: Status and Path Forward Rick King International AIDS Vaccine Initiative Thailand 2011 Acknowledgements IAVI R&D Chris Parks Wayne Koff Mike Caulfield ld Adrian McDermott Thomas

More information

Development of prophylactic vaccines against HIV-1

Development of prophylactic vaccines against HIV-1 Schiffner et al. Retrovirology 2013, 10:72 REVIEW Open Access Development of prophylactic vaccines against HIV-1 Torben Schiffner 1, Quentin J Sattentau 1* and Lucy Dorrell 2,3 Abstract The focus of most

More information

The Third D: Long Term Solutions to End the Epidemic. Mitchell Warren Executive Director, AVAC 12 February 2014

The Third D: Long Term Solutions to End the Epidemic. Mitchell Warren Executive Director, AVAC 12 February 2014 The Third D: Long Term Solutions to End the Epidemic Mitchell Warren Executive Director, AVAC 12 February 2014 Key clinical trial milestones: HIV vaccine research First HIV vaccine trial opens Phase

More information

Combinatorial Vaccines for AIDS and other Infectious Diseases

Combinatorial Vaccines for AIDS and other Infectious Diseases Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Combinatorial Vaccines for AIDS

More information

How has the Polio Eradication Initiative influenced the global AIDS response? Bradley S. Hersh, MD, MPH

How has the Polio Eradication Initiative influenced the global AIDS response? Bradley S. Hersh, MD, MPH How has the Polio Eradication Initiative influenced the global AIDS response? Bradley S. Hersh, MD, MPH Presentation Outline Big history of global HIV epidemic Current status of HIV and the global AIDS

More information

Immunogens and Antigen Processing: Report from a Global HIV Vaccine Enterprise Working Group

Immunogens and Antigen Processing: Report from a Global HIV Vaccine Enterprise Working Group report Immunogens and Antigen Processing: Report from a Global HIV Vaccine Enterprise Working Group John Mascola, C Richter King & Ralph Steinman on behalf of a Working Group convened by the Global HIV

More information

Update on Biomedical Prevention. Thomas C. Quinn, MD, MSc

Update on Biomedical Prevention. Thomas C. Quinn, MD, MSc Update on Biomedical Prevention Thomas C. Quinn, MD, MSc Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health

More information

GLOBAL INVESTMENT IN HIV CURE RESEARCH AND DEVELOPMENT IN 2017 AFTER YEARS OF RAPID GROWTH FUNDING INCREASES SLOW

GLOBAL INVESTMENT IN HIV CURE RESEARCH AND DEVELOPMENT IN 2017 AFTER YEARS OF RAPID GROWTH FUNDING INCREASES SLOW GLOBAL INVESTMENT IN HIV CURE RESEARCH AND DEVELOPMENT IN 2017 AFTER YEARS OF RAPID GROWTH FUNDING INCREASES SLOW TOWARDS AN CURE PEOPLE FOCUSED SCIENCE DRIVEN JULY 2018 A GLOBAL STRATEGIC APPROACH TOWARDS

More information

Submitted electronically to:

Submitted electronically to: Submitted electronically to: ODOARRFI19@nih.gov Maureen Goodenow, PhD Associate Director of AIDS Research, NIH Director, Office of AIDS Research (OAR) National Institutes of Health 5601 Fishers Lane. Room

More information

JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018

JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018 1 JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many

More information

Spike Trimer RNA. dsdna

Spike Trimer RNA. dsdna Spike Trimer RNA dsdna Spike Trimer RNA Spike trimer subunits xxx gp120: receptor and coreceptor binding xxxxxxx gp41: membrane anchoring and target cell fusion dsdna Spike Trimer HIV gp120 binds to host

More information

Developing TB Vaccine Clinical Trial Capacity Aeras Perspective. Vicky Cardenas, PhD, JD

Developing TB Vaccine Clinical Trial Capacity Aeras Perspective. Vicky Cardenas, PhD, JD Developing TB Vaccine Clinical Trial Capacity Aeras Perspective Vicky Cardenas, PhD, JD ASEAN-EU STI Days 21-23 January 2014 Aeras Founded in 2003 Mission: Develop improved TB vaccines that are affordable

More information

HIV vaccine research and development

HIV vaccine research and development HIV vaccine research and development What is an HIV vaccine and how does it work? An HIV vaccine is a substance given to the body to teach it to defend itself against HIV. A successful preventative HIV

More information

Ongoing HVTN Trials. Protocol N Trial Collaborators HVTN HVTN VRC DAIDS. Study Product(s)

Ongoing HVTN Trials. Protocol N Trial Collaborators HVTN HVTN VRC DAIDS. Study Product(s) HVTN 076 17 HVTN DNA multiclade rad5 multiclade 09/2011 The study looks at the immune response of genital and rectal tissues to injections of a DNA vaccine followed by a recombinant adenovirus serotype

More information

Universal Influenza Vaccine Development

Universal Influenza Vaccine Development Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Universal Influenza Vaccine Development 2016 Global Vaccine and Immunization

More information

CPRIT Overview. Cancer Centers Administrators Forum April 4, 2016

CPRIT Overview. Cancer Centers Administrators Forum April 4, 2016 CPRIT Overview Cancer Centers Administrators Forum April 4, 2016 CPRIT s Unique Role in the Fight Against Cancer Overview: Created by the Texas Legislature and citizens in 2007 $3 billion over 10 years

More information

HIV Vaccine Conference

HIV Vaccine Conference HIV Vaccine Conference The B cell response to HIV and HIV vaccines: From broadly neutralizing to non-neutralizing antibodies In memory of Dr. Charles Mérieux Organized by Fondation Mérieux Les Pensières

More information

T W O D E C A D E S, O N E M E S S A G E : P R E V E N T I O N M AT T E R S

T W O D E C A D E S, O N E M E S S A G E : P R E V E N T I O N M AT T E R S 8 7 6 5 4 3 2 1 V 7 YEARS AND COUNTING... VI IV III II AVAC? 4 to an AIDS Vaccine? 3 2 AIDS VACCINE ADVOCACY COALITION MAY 2001 AIDS VACCINE ADVOCACY COALITION MAY 2000 1 HOW DO YOU FIGHT A DISEASE OF

More information

Roadmaps as a Vehicle for Addressing Large- Scale Public Health Challenges: Lessons from the Malaria Vaccine Technology Roadmap

Roadmaps as a Vehicle for Addressing Large- Scale Public Health Challenges: Lessons from the Malaria Vaccine Technology Roadmap Background to development of vaccine roadmaps, to include priority areas for research, product development, capacities, and policy and commercialization Roadmaps as a Vehicle for Addressing Large- Scale

More information

AIDSVaccine2010 Atlanta, Georgia Willy Bogers. NIH HIVRad Grant nr 5P01AI066287

AIDSVaccine2010 Atlanta, Georgia Willy Bogers. NIH HIVRad Grant nr 5P01AI066287 HIV-1 envelope-cd4 receptor complexes elicit broad T- and B- cell immune responses as well as cross-reactive neutralizing antibodies in Rhesus macaques NIH HIVRad Grant nr 5P01AI066287 AIDSVaccine2010

More information

Report. of the. WHO-UNAIDS Vaccine Advisory Committee (VAC) Geneva, May 1-3, 2012

Report. of the. WHO-UNAIDS Vaccine Advisory Committee (VAC) Geneva, May 1-3, 2012 Report of the WHO-UNAIDS Vaccine Advisory Committee (VAC) and Scientific Briefing on the biomedical HIV/AIDS prevention landscape and consequences for HIV vaccine development Geneva, May 1-3, 2012 Contents

More information

Start Date* Sites Description

Start Date* Sites Description HVTN 076 17 HVTN HVTN 084 100 HVTN HVTN 085 90 HVTN HVTN 096 96 HVTN IPPOX EuroVacc GSID USMHRP HVTN 098 94 HVTN Inovio clade B AIDSVAX B/E clade C NYVAC clade C PENNVAX-GP IL-12 adjuvant September-11

More information

Virus Panels for Assessing Vaccine-Elicited Neutralizing Antibodies

Virus Panels for Assessing Vaccine-Elicited Neutralizing Antibodies Virus Panels for Assessing Vaccine-Elicited Neutralizing Antibodies Michael Seaman, Ph.D. Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Harvard Medical School J. Virol.

More information

TRANS-NIH PLAN FOR HIV RELATED RESEARCH

TRANS-NIH PLAN FOR HIV RELATED RESEARCH National Institutes of Health FY 2018 TRANS-NIH PLAN FOR HIV RELATED RESEARCH Prepared by the Office of AIDS Research Maureen M. Goodenow, Ph.D. NIH Associate Director for AIDS Research and Director, Office

More information

BARDA INFLUENZA PROGRAM OVERVIEW

BARDA INFLUENZA PROGRAM OVERVIEW BARDA INFLUENZA PROGRAM OVERVIEW Drs. Armen Donabedian and Michael Wathen Vaccines and Therapeutics Resilient People. Healthy Communities. A Nation Prepared. 0 BARDA Overview 1 Perpetual challenge of responding

More information

Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study

Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study Note: I have added some clarifying comments to the slides -- please click on Comments under View to see them. Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a

More information

Generation of Robust Antibody Responses to HIV-1 MPER Antigens in Mice Reconstituted with Cultured B cells

Generation of Robust Antibody Responses to HIV-1 MPER Antigens in Mice Reconstituted with Cultured B cells Generation of Robust Antibody Responses to HIV-1 MPER Antigens in Mice Reconstituted with Cultured B cells T. Matt Holl 1, Masayuki Kuraoka 1, Dongmei Liao 1, Laurent Verkoczy 2, M. Anthony Moody 2, Munir

More information

CONTRIBUTED SESSION 1

CONTRIBUTED SESSION 1 IMPROVING TRANSPARENCY IN CLINICAL TRIAL COSTS FOR PARTICIPANTS: NATIONAL CANCER INSTITUTE (NCI) NATIONAL COVERAGE ANALYSIS INITIATIVE SUPPORTED BY THE NCI S CANCER TRIALS SUPPORT UNIT Lawrence R Ragard

More information

PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM

PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures

More information

Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses

Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses Weimin Liu University of Alabama at Birmingham Introduction and Rationale Virus-like particles (VLPs)

More information

Developing a Target Product Profile for a Preventive HIV Vaccine

Developing a Target Product Profile for a Preventive HIV Vaccine Developing a Target Product Profile for a Preventive HIV Vaccine Topics to be Covered Overview of TPPs What are they? What is the purpose and benefit of using a TPP? What is usually in a TPP? What are

More information

Vaccine Innovation and Adult Immunization Landscape

Vaccine Innovation and Adult Immunization Landscape Vaccine Innovation and Adult Immunization Landscape National Adult and Influenza Immunization Summit, May 12-14, 2015 Phyllis Arthur Senior Director Vaccines, Immunotherapeutics & Diagnostics Policy parthur@bio.org

More information

Supplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood

Supplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood Supplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood tree illustrating CRF01_AE gp120 protein sequence relationships between 107 Envs sampled in the RV144 trial

More information

RIGHT (Research Investment for Global Health Technology, Korean GHIT) November 2017

RIGHT (Research Investment for Global Health Technology, Korean GHIT) November 2017 RIGHT (Research Investment for Global Health Technology, Korean GHIT) November 2017 ROK intends to create a new public-private partnership modeled after successful Japanese GHIT fund Research Investment

More information

HIV Vaccine. Sunee Sirivichayakul, Ph.D. Faculty of Medicine Chulalongkorn University. August 22, 2014

HIV Vaccine. Sunee Sirivichayakul, Ph.D. Faculty of Medicine Chulalongkorn University. August 22, 2014 HIV Vaccine Sunee Sirivichayakul, Ph.D. Faculty of Medicine Chulalongkorn University August 22, 2014 Immunity Natural immunity Active natural immunity e.g., infection Passive natural immunity e.g., trans-placental

More information

Cent Gardes Conference: HIV Vaccines. Organized by Fondation Mérieux «Les Pensières» Fondation Mérieux Conference Center Veyrier du Lac - France

Cent Gardes Conference: HIV Vaccines. Organized by Fondation Mérieux «Les Pensières» Fondation Mérieux Conference Center Veyrier du Lac - France Cent Gardes Conference: HIV Vaccines Organized by Fondation Mérieux «Les Pensières» Fondation Mérieux Conference Center Veyrier du Lac - October 6 to 8, 2017 Steering Committee Members Françoise Barré-Sinoussi

More information

Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives. Oncology Therapeutic Area Janssen Research & Development, LLC

Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives. Oncology Therapeutic Area Janssen Research & Development, LLC Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives Oncology Therapeutic Area Janssen Research & Development, LLC The patients are waiting. Dr. Paul Janssen To Our Potential

More information

Malaria Vaccine Pipeline

Malaria Vaccine Pipeline Malaria Vaccine Pipeline Perspectives and Challenges Carla Botting World Vaccine Congress Asia 2008 3 June 2008 Discussion Points Scope of the problem: the burden and challenge of malaria Malaria vaccine

More information

A VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART

A VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART BIOE 301 LECTURE 10 MITALI BANERJEE A VACCINE FOR HIV HIV HAART Visit wikipedia.org and learn the mechanism of action of the five classes of antiretroviral drugs. (1) Reverse transcriptase inhibitors (RTIs)

More information

Chikungunya Vaccines in the Pipeline

Chikungunya Vaccines in the Pipeline Chikungunya Vaccines in the Pipeline Health impact Public health burden : 1.3 billion people live in areas endemic for Chikungunya. Prevalent in ~60 countries over the world Has high attack rates and the

More information

The Publication on AIDS Vaccine Research VOLUME 22, ISSUE 2 JULY 2018

The Publication on AIDS Vaccine Research   VOLUME 22, ISSUE 2 JULY 2018 The Publication on AIDS Vaccine Research WWW.IAVIREPORT.ORG VOLUME 22, ISSUE 2 JULY 2018 FROM THE EDITOR In a few weeks, the AIDS 2018 meeting will kick off in Amsterdam. It will be the 22nd annual conference,

More information

HPTN 071 (PopART) Population Effects of Antiretroviral Therapy to Reduce HIV Transmission

HPTN 071 (PopART) Population Effects of Antiretroviral Therapy to Reduce HIV Transmission HPTN 071 (PopART) Population Effects of Antiretroviral Therapy to Reduce HIV Transmission TWEET LIVE #HPTN071 DIAL IN NUMBER FOR AUDIO: 1-866-740-1260 BROADCAST AUDIO CODE: 4011527 PLEASE USE THE CHAT

More information

TB Vaccine Development Strategy Overview

TB Vaccine Development Strategy Overview TB Vaccine Development Strategy Overview October 28, 2014 Angeline Nanni, MBA, MS Aeras Director, Global Access TB is Mother Nature s number one killer over the past centuries TB is spread through the

More information

CROI 2016 Review: Immunology and Vaccines

CROI 2016 Review: Immunology and Vaccines Frontier AIDS Education and Training Center CROI 2016 Review: Immunology and Vaccines Meena Ramchandani MD MPH Acting Instructor, University of Washington March 2016 This presentation is intended for educational

More information